Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action?

Author(s): M. Galuppo, E. Mazzon, S. Giacoppo, O. Bereshchenko, S. Bruscoli, C. Riccardi, P. Bramanti

Journal Name: Current Molecular Medicine

Volume 15 , Issue 10 , 2015

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Aberrant activation of Wnt/β-catenin signaling pathway is commonly associated to cancer development. However, molecular mechanisms controlling Wnt/β-catenin signaling pathway have been clarified only in part. Here, we show that β-catenin is differently modulated in patients with multiple sclerosis (MS), displaying that different pharmacological treatments used for clinical MS management cause different nuclear expression levels of β-catenin. Proteins extracted by peripheral blood mononuclear cells were assessed to evaluate the western blot expression levels of β-catenin. Analyzing our results, we realized that β-catenin is totally inhibited by Natalizumab and could have a role in MS management. This could offer new promising studies focused on the possible therapeutic control of β-catenin translocation.

Keywords: Relapsing/remitting multiple sclerosis, first diagnosis patients, Wnt/β-catenin pathway, natalizumab, interferon-beta, neurodegenerative disease.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 25 November, 2015
Page: [990 - 993]
Pages: 4
DOI: 10.2174/1566524016666151123114825
Price: $65

Article Metrics

PDF: 15